On January 2, 2017, in connection with his appointment as President and Chief Commercial Officer of Eagle Pharmaceuticals, Inc., or the Company, David Pernock resigned from the board of directors of the Company, or the Board, (including his position as a member of the Board's Nominating and Corporate Governance Committee). In addition, in connection with Mr. Pernock's appointment, Scott Tarriff resigned from his position as President of the Company, effective January 2, 2017. Mr. Tarriff will continue to serve as the Company's Chief Executive Officer and as a member of the Board.